Back to Condition
Chordoma
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Condition

Chordoma

Chordoma is a rare, slow-growing cancerous tumor that arises from notochord remnants along the spine, often causing pain, neurological symptoms, and potential recurrence.

Overview

A chordoma is a rare type of cancerous tumor that can occur anywhere along the spine, from the base of the skull to the tailbone. These tumors grow slowly, gradually extending into the surrounding bone and soft tissue. They often recur after treatment, and in about 40 percent of cases, the cancer spreads to other areas of the body, such as the lungs.

Symptoms

As a chordoma grows, it puts pressure on adjacent areas of the brain or spinal cord. Symptoms vary based on the tumor's location:

  • General spinal chordoma: Pain, weakness, or numbness in the back, arms, or legs.
  • Occipital chordoma (base of the skull): Double vision (diplopia) and headaches.
  • Coccygeal chordoma (tailbone): A palpable lump under the skin and potential bladder or bowel dysfunction.

Causes & Risk Factors

Changes in the TBXT gene are associated with chordoma. This gene provides instructions for making the brachyury protein, a transcription factor critical for early spinal development. In human embryos, the notochord is the precursor to the spinal column. While it typically disappears before birth, some cells may remain in the spine or skull base; in rare cases, these cells grow uncontrollably, leading to a chordoma.

  • Genetic factors: An inherited duplication of the TBXT gene is linked to an increased risk of developing the condition.
  • Sporadic cases: In many individuals, TBXT gene changes occur only in tumor cells and are not inherited.
  • Demographics: Chordomas typically occur in adults aged 40 to 70, though 5 percent are diagnosed in children. Males are affected about twice as often as females.

Frequency

Chordomas are rare, occurring in approximately 1 per million individuals each year. They comprise fewer than 1 percent of all tumors affecting the brain and spinal cord.

Inheritance

When associated with an inherited TBXT gene duplication, the condition follows an autosomal dominant pattern of inheritance. In these cases, one copy of the altered gene is sufficient to increase the risk of the disorder. Most cases, however, are sporadic and occur in people with no family history of the condition.

Frequently Asked Questions

Surgery aims to remove as much tumor as safely possible; however, complete resection is often limited by proximity to cranial nerves and brainstem. Modern endoscopic endonasal approaches can improve access while preserving function. Adjuvant high‑dose proton or carbon‑ion beam therapy is the preferred radiation modality because it delivers a concentrated dose with minimal spill to surrounding tissue, reducing the risk of neurological deficits. Combined surgery + particle therapy offers the best local control rates (≈70‑80 % at 5 years) but patients may still experience persistent diplopia, facial numbness, or hormonal changes depending on the structures involved. How often should imaging be performed after treatment to catch a recurrence early, and what signs should prompt an urgent scan?::Most centers schedule MRI of the primary site every 3–6 months for the first 2 years, then annually if stable. If the original tumor was in the sacrum, a CT of the pelvis may be added. New or worsening localized pain, new neurologic weakness, changes in bowel or bladder function, or the appearance of a palpable mass should trigger an immediate MRI, even if the routine interval has not yet arrived. Can genetic testing for TBXT or other mutations help my family understand their risk, and is it covered by insurance?::Testing the TBXT gene (including duplication analysis) can identify hereditary predisposition, which is present in a minority of chordoma families. If a pathogenic variant is found, first‑degree relatives can be offered predictive testing. Many insurers cover germline testing when there is a personal or family history of chordoma, but coverage varies; a pre‑authorization request with a detailed family pedigree often improves approval chances. What non‑pharmacologic strategies can help manage chronic pain from a chordoma that cannot be fully resected?::A multidisciplinary pain program is recommended. Physical therapy focused on core stabilization can reduce mechanical strain, while gentle stretching helps maintain mobility. Low‑impact aerobic exercise (e.g., swimming, stationary cycling) improves circulation and may lessen pain perception. Cognitive‑behavioral therapy and mindfulness‑based stress reduction have shown benefit in cancer‑related chronic pain. For refractory cases, interventional options such as epidural steroid injections or radiofrequency ablation may be considered in consultation with a pain specialist.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

kontakt@hittavard.se

Ⓒ 2024. Alla rättigheter förbehålls av juxt ab